Related Experiment Videos
Poly (ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia
L Liaudet1, A Szabó, F G Soriano
1Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.
Shock (Augusta, Ga.)
|August 18, 2000
Summary
Poly (ADP-ribose) synthetase (PARS) activation contributes to intestinal injury after mesenteric ischemia-reperfusion. Inhibiting PARS protects against this damage and reduces organ dysfunction, suggesting a therapeutic target.
Area of Science:
- Biomedical Science
- Physiology
- Pathology
Background:
- Peroxynitrite-induced DNA strand breaks activate poly (ADP-ribose) synthetase (PARS).
- PARS activation leads to cellular energy depletion and organ dysfunction.
- The role of PARS in intestinal response to mesenteric ischemia-reperfusion injury is not fully understood.
Purpose of the Study:
- To investigate the role of PARS activation in the inflammatory and functional response of the intestine to mesenteric ischemia-reperfusion injury.
- To evaluate the therapeutic potential of PARS inhibition in mitigating reperfusion-related damage.
Main Methods:
- Rats and PARS knockout mice were subjected to mesenteric artery occlusion and reperfusion.
- PARS activity was measured using radiolabeled NAD+ incorporation.
- Histological damage, mucosal hyperpermeability (FD4), neutrophil infiltration (myeloperoxidase), and lipid peroxidation (malondialdehyde) were assessed.
- Pharmacological inhibitors of nitric oxide synthase and PARS were used.
Main Results:
- Increased PARS activity was observed in rat intestinal mucosa post-reperfusion.
- PARS inhibition significantly reduced mucosal damage, hyperpermeability, and neutrophil infiltration.
- PARS knockout mice showed significant protection against histological damage, barrier dysfunction, and remote organ injury.
- Inhibition of peroxynitrite production also ameliorated the injury.
Conclusions:
- PARS plays a critical role in mediating intestinal injury and dysfunction during both early and late phases of mesenteric reperfusion.
- Pharmacological inhibition of PARS offers a potential therapeutic strategy to protect tissues from reperfusion injury.
- Targeting PARS may reduce systemic organ damage following ischemic events.